Donapril

Quick links to important sections

Donapril

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Donapril

What is Donapril?

Donapril is a pharmaceutical medication classified as an ACE (Angiotensin-Converting Enzyme) inhibitor. It is primarily used in the management of cardiovascular conditions, specifically hypertension and certain types of heart failure.

Mechanism of Action

The medication works by inhibiting the activity of the angiotensin-converting enzyme. This enzyme is responsible for the conversion of angiotensin I into angiotensin II, a potent chemical that causes blood vessels to contract and narrow. By reducing the production of angiotensin II, Donapril allows blood vessels to remain more relaxed and dilated. This process results in lowered blood pressure and reduces the workload on the heart, making it easier for the organ to pump blood throughout the body.

Therapeutic Purpose

Donapril is utilized to help stabilize blood pressure levels in individuals with chronic hypertension. By maintaining lower pressure within the vascular system, the medication helps to decrease the long-term strain on the heart and kidneys. In the context of heart failure, it is used to improve cardiac efficiency and manage the progression of the condition.

Regulatory References

  1. Enalapril: MedlinePlus Drug Information
  2. Enalapril on WHO's Essential Medicines List

What side effects are possible with Donapril?

Possible Side Effects and Safety Information

The safety profile of Donapril (Enalapril maleate) is characterized by a range of officially documented adverse reactions, which are classified by frequency and the body system affected, consistent with regulatory labeling.

Frequency-Classified Adverse Reactions

The documentation classifies certain effects based on how often they have been reported in clinical use:

  • Very Common (Affecting 1 in 10 or more people): Cough, dizziness, and asthenia (lack of strength).
  • Common (Affecting fewer than 1 in 10 people): Headache, fatigue, nausea, diarrhea, and hypotension (low blood pressure).

Serious Adverse Reactions and Safety Constraints

Official regulatory documents highlight the potential for serious adverse reactions. The most significant concern is Angioedema, which is rapid swelling of the face, tongue, glottis, and/or larynx, and is a life-threatening condition documented with ACE inhibitors. Other serious documented reactions include Acute Renal Failure and Hepatic Failure, although these are rare.

Safety constraints are placed on specific patient groups. Use during the second and third trimesters of pregnancy is explicitly associated with the risk of fetal injury and death. Furthermore, excessive blood pressure drop (Hypotension) is noted as being most likely to occur following the initial dose, particularly in patients with pre-existing volume depletion. The medicine is contraindicated in patients with a history of angioedema related to prior ACE inhibitor therapy.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Donapril (Enalapril maleate) is officially documented to present with severe manifestations primarily related to excessive lowering of blood pressure. The most prominent signs include severe hypotension (abnormally low blood pressure) and bradycardia (slowed heart rate). Additional documented symptoms include orthostatic effects and dizziness. Laboratory findings may show severe hyperkalemia or hyponatremia.

A critical, life-threatening manifestation documented in regulatory information is Angioedema involving the tongue, glottis, or larynx, which carries the risk of fatal airway obstruction. For this reason, or any suspected overdose, official guidance requires patients to seek immediate medical attention and contact emergency services without delay. Severe hypotension is also associated with the potential for serious outcomes, including acute renal failure, myocardial infarction, or cerebrovascular accident, especially in patients with pre-existing heart or vascular conditions.

Overdose management is uniformly described as symptomatic and supportive. Procedural measures include placing the patient in the supine position and initiating intravenous volume expansion to counteract severe hypotension. Regulatory documents require a prolonged period of hospital monitoring—often lasting 12 to 36 hours—to check vital signs, serum electrolytes, and renal function (BUN/creatinine). The active metabolite, Enalaprilat, is recognized as dialyzable.

Therapeutic Uses of Donapril

Donapril (Donepezil) is a therapeutic option commonly used to help with symptoms related to systemic imbalance across conditions characterized by periods of heightened symptoms, such as those involving recurrent or episodic manifestations.

The medication is considered relevant for managing symptoms that interfere with daily functioning, addressing the symptomatic burden of conditions presenting with systemic or localized discomfort, including those associated with acute or disruptive episodes. It is applied across domains where additional symptomatic support is needed. Specifically, the medication is used to address symptomatic manifestations in patients with Alzheimer’s disease.

This medication may assist with maintaining functional stability during symptomatic periods, which is often used during phases when symptoms become more noticeable. By supporting general well-being, Donapril contributes to improved comfort and helps maintain a sense of stability for patients. It provides support that helps ease the overall symptom burden.

This supportive relief is provided when symptoms interfere with routine activities, and it is relevant when supportive symptom management is appropriate.


Quick Fact: Relief for Symptoms That Interfere with Daily Functioning

Regulatory References

  1. NIH MedlinePlus Drug Information for donepezil

Eligibility and Restrictions for Use

Donapril (Enalapril maleate) is an Angiotensin-Converting Enzyme (ACE) inhibitor whose use is governed by strict regulatory eligibility rules.

Contraindicated Populations

Official labeling contraindicates Donapril use in several patient groups, primarily due to safety risks. Patients must not use this medicine if they have a history of angioedema related to a previous ACE inhibitor or if they have hereditary or idiopathic angioedema. Use is also strictly contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury or death. Furthermore, it is prohibited to use Donapril concurrently with Aliskiren in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m²).

Age and Organ Function Eligibility

Population Group Regulatory Status
Adults Established for approved indications.
Children > 1 month Approved for hypertension only.
Infants leq 1 month Not recommended (insufficient data).

Use is not recommended in pediatric patients with severe renal impairment (GFR < 30 mL/min/1.73 m²). For older adults and adults with impaired renal function (creatinine clearance < 80 mL/min), initial dosage adjustment and careful monitoring are required. The medicine is not recommended during the first trimester of pregnancy or while breastfeeding newborns or premature infants.

What should I know about interactions with other medicines?

The interaction profile for Donapril (Enalapril maleate) is primarily defined by high-risk, classified combinations and documented physiological effects. The co-administration of Sacubitril/Valsartan (a Neprilysin inhibitor) is formally contraindicated due to an increased risk of angioedema; a mandatory separation period of 36 hours is required when switching between these agents. The combination with the direct renin inhibitor Aliskiren is contraindicated only in patients with diabetes mellitus or those with renal impairment (GFR less than 60 mL/min/1.73 m^2).

Pharmacodynamic risks include the potential for hyperkalemia when combined with Potassium-Sparing Diuretics, Potassium Supplements, or certain Salt Substitutes. Concomitant use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), especially in patients with pre-existing renal compromise or who are volume-depleted, increases the risk of renal function deterioration. The co-administration with other antihypertensive agents can lead to an additive hypotensive effect.

A critical pharmacokinetic interaction is observed with Lithium, as Donapril reduces its renal clearance, resulting in significantly increased serum Lithium concentrations and an elevated risk of toxicity. The medicine's absorption is officially documented as not influenced by food, and interactions with herbal products have not been formally established in regulatory documents.

Mechanism of Action

Targeting the Acetylcholinesterase Enzyme

Donapril acts as a reversible and non-competitive inhibitor of the enzyme acetylcholinesterase (AChE), primarily within the central nervous system (CNS). This targeted enzyme blockade prevents the rapid breakdown of the key neurotransmitter acetylcholine (ACh) in the synaptic clefts. This results in an immediate increase in the synaptic concentration of ACh available to activate postsynaptic receptors.


Enhancing Cholinergic Signaling

By increasing the synaptic concentration and duration of action of acetylcholine, the drug effectively enhances and sustains cholinergic neurotransmission in neural pathways. This modulation is relevant for pathways underlying complex cognitive functions, contributing to the observed systemic effect on neural circuit activity. This process results in sustained activation of cholinergic receptors and enhanced signaling within neural networks.


Supporting Neurophysiological Stability

Beyond its main enzyme-blocking action, the mechanism of Donapril may also encompass non-cholinergic effects, such as reduced neuroinflammation and modulation of cellular survival pathways within the central nervous system. This dual-layer mechanism may involve interaction with systems associated with cellular stress response, potentially influencing the status of neurons.

Dosage and Administration Information

How Donapril is Used

Donapril (Enalapril maleate) is an ACE inhibitor provided with specific instructions for use regarding administration routes, standard dosing, and necessary adjustments. These instructions define the proper usage of the medication.


Administration and Forms

Donapril is primarily taken orally in the form of a tablet or a reconstituted solution. The active metabolite, Enalaprilat, is also available for intravenous (IV) administration in settings where oral therapy is not feasible. Tablets should be swallowed whole.

Official Dosing Regimens

Dosing is highly structured, beginning with a low starting dose and gradually increasing as needed, which is known as titration.

Indication Starting Dose (Adult) Maximum Daily Dose (Adult)
Hypertension 5 mg once daily 40 mg
Heart Failure 2.5 mg twice daily 40 mg (in divided doses)

Frequency and Contextual Instructions

Donapril is typically taken once daily for hypertension, but may be taken twice daily (e.g., for heart failure). The medication can be taken with or without food, as its absorption is not affected by meals. The full desired effect, such as the full antihypertensive action, may take several weeks to develop.

Population-Specific Adjustments

Dose modification is required for certain groups. For patients with impaired kidney function (Creatinine Clearance le 30 mL/min), the initial dose is reduced to 2.5 mg once daily. Dosing for older adults should also consider their renal function.

Recent Clinical Evidence

Donapril: Recent Clinical Evidence

Summary of Investigated Pathways

Research has explored Donapril's investigated effects on pain pathways. Studies have also evaluated whether the treatment was associated with measured changes in joint mobility. Researchers have examined the treatment’s studied effects on markers related to the underlying pathology of the disease.


Primary Research Findings

Controlled studies evaluated the treatment's measured outcomes in cases of mild to moderate pain. Research included geriatric populations, and data specific to this group were collected and evaluated.

  • Pain Management: Research examined the effects of the drug on neuropathic pain symptoms across various clinical trials.
  • Chronic Conditions: Studies have investigated the potential association with measured changes in quality of life metrics in individuals with chronic conditions.
  • Inflammatory Markers: Research has explored whether the drug is associated with changes in inflammatory markers over time.

Combination Therapy Research

Studies evaluated whether the combination therapy was associated with a reduction in the frequency of migraines compared to placebo. Research in this area also examined outcomes for individuals who had not responded to traditional treatment approaches.

Some research compared this approach to monotherapy and reported the measured outcomes. Studies evaluated variables related to drug absorption and measured patient tolerance. Research also focused on identifying potential drug-drug interactions when the treatment was administered with common concomitant medications.

Frequently Asked Questions (FAQ)

Common questions about Donapril (FAQ)

Q: Why does Donapril sometimes cause digestive issues like nausea or diarrhea?

Official documentation indicates that nausea and diarrhea are reported as common adverse reactions experienced by users of Donapril. These regulatory documents note the frequency of these effects but do not generally provide a detailed physiological explanation for why they occur.

Q: Is it safe to consume alcohol while undergoing treatment with Donapril?

Regulatory safety information suggests that alcohol may have an additive effect with Donapril in lowering blood pressure. This combination may increase the risk of symptoms like dizziness, fainting, or changes in heart rate. Official safety information indicates caution may be warranted regarding alcohol consumption.

Q: Can certain cold or allergy medicines interfere with Donapril?

Official product information advises caution when Donapril is used alongside certain medicines that contain ingredients like ephedrine, noradrenaline, or adrenaline. These ingredients are sometimes found in preparations used to treat low blood pressure, asthma, or allergies, and their combination carries a potential for interaction.

Q: Does Donapril interact with medications for depression or anxiety?

Official documents note that adverse psychiatric reactions, including depression and confusion, have been reported by users. While specific interaction details for every antidepressant or anxiety medication are not universally detailed in general regulatory labeling, official reports indicate that psychiatric effects are possible.

Q: What is the correct general procedure if a dose of Donapril is forgotten?

Official instructions state that a missed dose should typically be skipped entirely to avoid taking too much medicine at once. The next dose should then be taken at the usual scheduled time. Regulatory information generally advises against taking a double dose to try to compensate for the skipped one.

Q: Why is Donapril commonly recommended to be taken in the evening before bed?

Official guidance sometimes suggests taking the first dose before bedtime. This recommendation is related to the fact that Donapril can cause dizziness or low blood pressure (hypotension) when treatment is initiated. Taking the initial dose before sleep is suggested as a way to manage the risk of these effects.

Q: Can Donapril be taken at a different time of day if it causes sleep disturbances?

Official documents report sleep disorders, including insomnia or dream abnormalities, as uncommon side effects. If a user is not experiencing dizziness after the first dose, the medicine can typically be taken at a consistent time that is convenient for them. Consistency in timing is generally emphasized by administration information.

Q: Are there warnings about Donapril and the risk of seizures?

Regulatory safety guides indicate that seizures may be a symptom related to severe underlying issues that can occur with Donapril use, such as kidney damage or significant electrolyte imbalances. Official safety guidance suggests awareness of this potential link, even though seizures are not listed as a primary side effect.

Q: Is muscle cramping a reported side effect of Donapril?

Official product information documents confirm that muscle cramps are an uncommon side effect associated with Donapril use. Official reporting suggests that this is an uncommon adverse reaction documented during clinical use.

Q: Can Donapril potentially cause problems with the heart rate or rhythm?

Regulatory safety information notes that Donapril can potentially lead to high potassium levels, a condition known as hyperkalemia. Hyperkalemia is associated with symptoms that can include a slow heartbeat or other abnormal heart rhythms.

Q: Does Donapril help with symptoms like agitation or aggression?

Official regulatory documents list depression and confusion as documented adverse psychiatric reactions reported by some users. However, the regulatory indications for the medicine do not include the treatment or management of specific behavioral symptoms such as agitation or aggression.

Q: Can Donapril worsen existing urinary problems or difficulties?

Regulatory documents acknowledge that adverse reactions related to kidney function have been reported by users. These documented effects include oliguria (decreased urination) and, in rare instances, acute renal failure. Regulatory documents indicate the need for careful consideration when used in patients with pre-existing urinary or renal issues.

Q: Is Donapril only used for mild or moderate stages of its treated condition?

Donapril is approved for treating both hypertension (high blood pressure) and heart failure. Regulatory labeling indicates the medicine's use for these primary conditions without typically restricting its use based on a standardized severity scale. Dosage adjustments are based on specific factors outlined in the prescribing information, such as kidney function.

How should Donapril be stored and disposed of?

How to Store and Dispose of Donapril

Official regulatory guidelines mandate specific conditions for storing and disposing of Donapril to ensure drug stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 °C to 25 °C (68 °F to 77 °F). Do not freeze and avoid excessive heat.
Handling Keep the medicine in its original container, tightly closed, and protect it from moisture and light.
Safety Keep Donapril strictly out of the sight and reach of children.
Stability Do not use the medicine after the expiration date printed on the packaging.

Disposal Instructions

Unused or expired Donapril should be disposed of via an authorized pharmaceutical take-back program or drug collection site. If a take-back program is unavailable, government guidelines require mixing the medicine with an undesirable substance (such as cat litter) before discarding it in sealed household trash. Do not flush Donapril down the toilet or pour it down a drain unless specifically instructed to do so by official sources.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Donapril found in:

A-Z Index: